Lenox Hill Radiology (LHR) in New York and New Jersey Imaging Network (NJIN) to add Nociscan across multiple sites
Aclarion, Inc., a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain and to expand Nociscan access across key markets in New York and New Jersey. The expansion plans build on previously established Nociscan sites with RadNet affiliates in both states and are driven by the increased availability of MR Spectroscopy (MRS) and enhanced remote operations capabilities within RadNet to meet growing market demand for Nociscan.
Health Technology Insights: iCAD and RamSoft Partner to Expand Profound AI Mammography in North America
“Expanding scanner access is a key element of our strategy to drive Nociscan to standard of care for patients with chronic low back pain,” said Brent Ness, Chief Executive Officer of Aclarion. “The additional sites RadNet is onboarding will help us enable more convenient access to grow scan volume in response to physician demand. It also underscores our strong relationship with this important national imaging provider.”
Lenox Hill Radiology (LHR) operates convenient, outpatient imaging centers located in the metropolitan New York area, and 79 total locations throughout New York state. LHR Park Avenue, a flagship site, initially adopted Nociscan to provide access to leading spine physicians in private practice and from globally recognized organizations such as Weill Cornell.
Health Technology Insights: Pluto Health Now Qualified Under Medicaid Tennessee, Expanding Access to Vital Care.
New Jersey Imaging Network (NJIN) is one of the largest imaging providers in NJ with 33 locations. NJIN-Union, in metro NJ, was the first site in NJ to adopt Nociscan to support both local physicians and out-of-market referrals through the convenience of Newark Liberty International Airport and Teterboro Airport.
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain and demonstrates a 97% surgical success rate when all Nociscan-identified pain positive discs are treated.
Health Technology Insights: Philips Chooses AWS as Preferred Cloud to Drive Innovation, Patient Care
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – GlobeNewswire
